Dr. Reddy Plans the Onset of P-III trial for DRL_RI (biosimilar, rituximab) in the Korea

 Dr. Reddy Plans the Onset of P-III trial for DRL_RI (biosimilar, rituximab) in the Korea

Dr. Reddy’s Laboratories Launches Versavo (biosimilar, bevacizumab) for Multiple Cancers in India

Shots:

  • The P-III trial involves assessing of DRL_RI vs Roche’s MabThera (rituximab) in 284 patients including 26 Koreans, with stage II-IV, CD20 positive, and follicular lymphoma previously treated have low tumor burden, evaluating its efficacy, safety, and immunogenicity
  • Dr. Reddy’s plan to evaluate DRL_RI in Korea while Paraxel to provide clinical research services and Korea’s MFDS has also approved P-III trial for DRL_RI on Wednesday
  • DRL_RI is a mAb and a biosimilar of Roche’s MabThera and will be targeted for lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis

Click here to­ read full press release/ article | Ref: KoreaBioMed | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post